1
|
Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW, Cerana S, Dictar MO, Bonvehi P, Tregnaghi JP, Fein L, Ashley D, Singh M, Hayes T, Playford G, Morrissey O, Thaler J, Kuehr T, Greil R, Pecherstorfer M, Duck L, Van Eygen K, Aoun M, De Prijck B, Franke FA, Barrios CHE, Mendes AVA, Serrano SV, Garcia RF, Moore F, Camargo JFC, Pires LA, Alves RS, Radinov A, Oreshkov K, Minchev V, Hubenova AI, Koynova T, Ivanov I, Rabotilova B, Minchev V, Petrov PA, Chilingirov P, Karanikolov S, Raynov J, Grimard D, McNeil S, Kumar D, Larratt LM, Weiss K, Delage R, Diaz-Mitoma FJ, Cano PO, Couture F, Carvajal P, Yepes A, Torres Ulloa R, Fardella P, Caglevic C, Rojas C, Orellana E, Gonzalez P, Acevedo A, Galvez KM, Gonzalez ME, Franco S, Restrepo JG, Rojas CA, Bonilla C, Florez LE, Ospina AV, Manneh R, Zorica R, Vrdoljak DV, Samarzija M, Petruzelka L, Vydra J, Mayer J, Cibula D, Prausova J, Paulson G, Ontaneda M, Palk K, Vahlberg A, Rooneem R, Galtier F, Postil D, Lucht F, Laine F, Launay O, Laurichesse H, Duval X, Cornely OA, Camerer B, Panse J, Zaiss M, Derigs HG, Menzel H, Verbeek M, Georgoulias V, Mavroudis D, Anagnostopoulos A, Terpos E, Cortes D, Umanzor J, Bejarano S, Galeano RW, Wong RSM, Hui P, Pedrazzoli P, Ruggeri L, Aversa F, Bosi A, Gentile G, Rambaldi A, Contu A, Marei L, Abbadi A, Hayajneh W, Kattan J, Farhat F, Chahine G, Rutkauskiene J, Marfil Rivera LJ, Lopez Chuken YA, Franco Villarreal H, Lopez Hernandez J, Blacklock H, Lopez RI, Alvarez R, Gomez AM, Quintana TS, Moreno Larrea MDC, Zorrilla SJ, Alarcon E, Samanez FCA, Caguioa PB, Tiangco BJ, Mora EM, Betancourt-Garcia RD, Hallman-Navarro D, Feliciano-Lopez LJ, Velez-Cortes HA, Cabanillas F, Ganea DE, Ciuleanu TE, Ghizdavescu DG, Miron L, Cebotaru CL, Cainap CI, Anghel R, Dvorkin MV, Gladkov OA, Fadeeva NV, Kuzmin AA, Lipatov ON, Zbarskaya II, Akhmetzyanov FS, Litvinov IV, Afanasyev BV, Cherenkova M, Lioznov D, Lisukov IA, Smirnova YA, Kolomietz S, Halawani H, Goh YT, Drgona L, Chudej J, Matejkova M, Reckova M, Rapoport BL, Szpak WM, Malan DR, Jonas N, Jung CW, Lee DG, Yoon SS, Lopez Jimenez J, Duran Martinez I, Rodriguez Moreno JF, Solano Vercet C, de la Camara R, Batlle Massana M, Yeh SP, Chen CY, Chou HH, Tsai CM, Chiu CH, Siritanaratkul N, Norasetthada L, Sriuranpong V, Seetalarom K, Akan H, Dane F, Ozcan MA, Ozsan GH, Kalayoglu Besisik SF, Cagatay A, Yalcin S, Peniket A, Mullan SR, Dakhil KM, Sivarajan K, Suh JJG, Sehgal A, Marquez F, Gomez EG, Mullane MR, Skinner WL, Behrens RJ, Trevarthe DR, Mazurczak MA, Lambiase EA, Vidal CA, Anac SY, Rodrigues GA, Baltz B, Boccia R, Wertheim MS, Holladay CS, Zenk D, Fusselman W, Wade III JL, Jaslowsk AJ, Keegan J, Robinson MO, Go RS, Farnen J, Amin B, Jurgens D, Risi GF, Beatty PG, Naqvi T, Parshad S, Hansen VL, Ahmed M, Steen PD, Badarinath S, Dekker A, Scouros MA, Young DE, Graydon Harker W, Kendall SD, Citron ML, Chedid S, Posada JG, Gupta MK, Rafiyath S, Buechler-Price J, Sreenivasappa S, Chay CH, Burke JM, Young SE, Mahmood A, Kugler JW, Gerstner G, Fuloria J, Belman ND, Geller R, Nieva J, Whittenberger BP, Wong BMY, Cescon TP, Abesada-Terk G, Guarino MJ, Zweibach A, Ibrahim EN, Takahashi G, Garrison MA, Mowat RB, Choi BS, Oliff IA, Singh J, Guter KA, Ayrons K, Rowland KM, Noga SJ, Rao SB, Columbie A, Nualart MT, Cecchi GR, Campos LT, Mohebtash M, Flores MR, Rothstein-Rubin R, O'Connor BM, Soori G, Knapp M, Miranda FG, Goodgame BW, Kassem M, Belani R, Sharma S, Ortiz T, Sonneborn HL, Markowitz AB, Wilbur D, Meiri E, Koo VS, Jhangiani HS, Wong L, Sanani S, Lawrence SJ, Jones CM, Murray C, Papageorgiou C, Gurtler JS, Ascensao JL, Seetalarom K, Venigalla ML, D'Andrea M, De Las Casas C, Haile DJ, Qazi FU, Santander JL, Thomas MR, Rao VP, Craig M, Garg RJ, Robles R, Lyons RM, Stegemoller RK, Goel S, Garg S, Lowry P, Lynch C, Lash B, Repka T, Baker J, Goueli BS, Campbell TC, Van Echo DA, Lee YJ, Reyes EA, Senecal FM, Donnelly G, Byeff P, Weiss R, Reid T, Roeland E, Goel A, Prow DM, Brandt DS, Kaplan HG, Payne JE, Boeckh MG, Rosen PJ, Mena RR, Khan R, Betts RF, Sharp SA, Morrison VA, Fitz-Patrick D, Congdon J, Erickson N, Abbasi R, Henderson S, Mehdi A, Wos EJ, Rehmus E, Beltzer L, Tamayo RA, Mahmood T, Reboli AC, Moore A, Brown JM, Cruz J, Quick DP, Potz JL, Kotz KW, Hutchins M, Chowhan NM, Devabhaktuni YD, Braly P, Berenguer RA, Shambaugh SC, O'Rourke TJ, Conkright WA, Winkler CF, Addo FEK, Duic JP, High KP, Kutner ME, Collins R, Carrizosa DR, Perry DJ, Kailath E, Rosen N, Sotolongo R, Shoham S, Chen T. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases 2019; 19:1001-1012. [DOI: 10.1016/s1473-3099(19)30310-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 12/25/2022]
|
5
|
Abulkhair O, Uslu R, Sezgin C, Büyükberber S, Darwish T, Isikdogan A, Gumus M, Dane F, Sevinc A, Halawani H, Uncu D, Marrero N, Tobler J, Soares C, Landis S, Moraes E, Gidekel R, Santillana S, Nunez P, Cagnolati S, Rodriguez JG. Abstract OT1-1-08: Clinical outcomes among ErbB2+ MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-ot1-1-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Lapatinib in combination with capecitabine is a standard of care treatment for ErbB2+ metastatic breast cancer (MBC) patients who have progressed after anthracyclines, taxanes and trastuzumab treatment. Results from the lapatinib pivotal trial showed that the addition of lapatinib to capecitabine increased median time to progression (TTP) even among heavily pre-treated patients (median of 4 prior lines of therapy). A post-hoc exploratory sub-group analysis of this trial suggested that earlier administration of lapatinib-capecitabine in MBC patients who progress after trastuzumab may produce better clinical outcomes. The TYCO study was designed to evaluate if early initiation of lapatinib-capecitabine in patients with ErbB2+ MBC who have progressed on trastuzumab-containing regimen improves TTP in comparison with a delayed start of the therapy.
Trial design: TYCO is an international, multicenter, prospective, observational study in 269 ErbB2+ MBC patients whose disease has progressed after treatment with trastuzumab in the metastatic setting. Two cohorts will be compared; Group 1: patients receiving lapatinib-capecitabine just after the first trastuzumab progression, and Group 2: patients receiving lapatinib-capecitabine after two or more lines of treatment after first trastuzumab progression. The study duration is of 12 months with data collection at baseline and approximately every 3 months thereafter.
Major Eligibility Criteria: 1. Females ≥18y with confirmed ErbB2+ MBC who have progressed after a previous trastuzumab-containing regimen,2. Pts eligible for standard therapy with lapatinib-capecitabine at approved conventional doses, as per local approved label.3. Pts eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, or receiving standard treatment with Lapatinib-capecitabine at conventional doses, for no longer than 10 weeks from the start of the treatment to the date of inclusion in the study;
Aims: Primary objective of this study is to determine if early switch to lapatinib-capecitabine in patients with ErbB2+ metastatic breast cancer who have progressed on trastuzumab containing regimen improves time to disease progression as determined by treating physician either clinically or radiologically. Secondary objectives include overall response rate and overall survival.
Statistical Methods: Kaplan-Meier plots will be used to describe the median TTP after start of lapatinib-capecetabine. Cox proportional hazard model will be developed to estimate the adjusted hazard ratio (and 95% confidence intervals) comparing TTP for the two treatment group using propensity score methods (trimmed sample, adjustment for the continuous propensity score measure, and doubly robust adjustment) to adjust for potential confounding by indication that may arise due to the non-randomised design.
Present and Target Accrual: Enrollment began in February 2010, and as per May 2012, 266 patients have been included from Turkey, Venezuela, Argentina, Saudi Arabia and Colombia.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT1-1-08.
Collapse
Affiliation(s)
- O Abulkhair
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - R Uslu
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - C Sezgin
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - S Büyükberber
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - T Darwish
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - A Isikdogan
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - M Gumus
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - F Dane
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - A Sevinc
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - H Halawani
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - D Uncu
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - N Marrero
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - J Tobler
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - C Soares
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - S Landis
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - E Moraes
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - R Gidekel
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - S Santillana
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - P Nunez
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - S Cagnolati
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| | - JG Rodriguez
- Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hosptial, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina
| |
Collapse
|